Suppr超能文献

用于量化使用非典型抗精神病药物治疗的患者的锥体外系副作用的笔迹运动运动学。

Handwriting movement kinematics for quantifying extrapyramidal side effects in patients treated with atypical antipsychotics.

机构信息

Department of Psychiatry, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.

出版信息

Psychiatry Res. 2010 May 15;177(1-2):77-83. doi: 10.1016/j.psychres.2009.07.005. Epub 2010 Apr 9.

Abstract

Ongoing monitoring of neuroleptic-induced extrapyramidal side effects (EPS) is important to maximize treatment outcome, improve medication adherence and reduce re-hospitalization. Traditional approaches for assessing EPS such as Parkinsonism, tardive akathisia, or dyskinesia rely upon clinical ratings. However, these observer-based EPS severity ratings can be unreliable and are subject to examiner bias. In contrast, quantitative instrumental methods are less subject to bias. Most instrumental methods have only limited clinical utility because of their complexity and costs. This paper describes an easy-to-use instrumental approach based on handwriting movements for quantifying EPS. Here, we present findings from psychiatric patients treated with atypical (second generation) antipsychotics. The handwriting task consisted of a sentence written several times within a 2 cm vertical boundary at a comfortable speed using an inkless pen and digitizing tablet. Kinematic variables including movement duration, peak vertical velocity and the number of acceleration peaks, and average normalized jerk (a measure of smoothness) for each up or down stroke and their submovements were analyzed. Results from 59 psychosis patients and 46 healthy comparison subjects revealed significant slowing and dysfluency in patients compared to controls. We observed differences across medications and daily dose. These findings support the ecological validity of handwriting movement analysis as an objective behavioral biomarker for quantifying the effects of antipsychotic medication and dose on the motor system.

摘要

持续监测神经阻滞剂引起的锥体外系副作用(EPS)对于最大化治疗效果、提高药物依从性和减少再住院至关重要。评估 EPS 的传统方法,如帕金森病、迟发性静坐不能或运动障碍,依赖于临床评分。然而,这些基于观察者的 EPS 严重程度评分可能不可靠,并且受到检查者偏见的影响。相比之下,定量仪器方法受到的偏见较少。由于其复杂性和成本,大多数仪器方法的临床应用有限。本文描述了一种基于手写运动的简单易用的仪器方法,用于量化 EPS。在这里,我们展示了接受非典型(第二代)抗精神病药物治疗的精神病患者的研究结果。手写任务包括使用无墨笔和数字化板在 2 厘米的垂直边界内舒适速度书写多次句子。运动学变量包括运动持续时间、峰值垂直速度和加速度峰值的数量,以及每个向上或向下笔画及其子运动的平均归一化急动度(衡量平滑度的指标)。来自 59 名精神病患者和 46 名健康对照者的结果显示,与对照组相比,患者的运动速度明显减慢且不流畅。我们观察到不同药物和每日剂量之间存在差异。这些发现支持手写运动分析作为一种客观的行为生物标志物,用于量化抗精神病药物和剂量对运动系统的影响的生态有效性。

相似文献

1
Handwriting movement kinematics for quantifying extrapyramidal side effects in patients treated with atypical antipsychotics.
Psychiatry Res. 2010 May 15;177(1-2):77-83. doi: 10.1016/j.psychres.2009.07.005. Epub 2010 Apr 9.
2
Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone.
Hum Mov Sci. 2009 Oct;28(5):633-42. doi: 10.1016/j.humov.2009.07.007. Epub 2009 Aug 18.
3
A quantitative measure of handwriting dysfluency for assessing tardive dyskinesia.
J Clin Psychopharmacol. 2015 Apr;35(2):168-74. doi: 10.1097/JCP.0000000000000277.
4
Quantitative measurement of handwriting in the assessment of drug-induced parkinsonism.
Hum Mov Sci. 2006 Oct;25(4-5):510-22. doi: 10.1016/j.humov.2006.02.004. Epub 2006 May 2.
6
The nature of bradykinesia in schizophrenia treated with antipsychotics.
Psychiatry Res. 2019 Mar;273:537-543. doi: 10.1016/j.psychres.2019.01.058. Epub 2019 Jan 15.
7
Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment.
Schizophr Res. 2008 Mar;100(1-3):97-107. doi: 10.1016/j.schres.2007.10.018. Epub 2007 Dec 11.
9
Extrapyramidal side-effects of antipsychotics in a randomised trial.
Br J Psychiatry. 2008 Oct;193(4):279-88. doi: 10.1192/bjp.bp.108.050088.
10
Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
Can J Psychiatry. 1994 Nov;39(9 Suppl 2):S76-80.

引用本文的文献

2
Handwriting Kinematics in Patients with Schizophrenia Treated with Long-Acting Injectable Atypical Antipsychotics: Results From the ALPINE Study.
Schizophr Bull Open. 2022 Mar 7;3(1):sgac018. doi: 10.1093/schizbullopen/sgac018. eCollection 2022 Jan.
3
Examining Motor Anticipation in Handwriting as an Indicator of Motor Dysfunction in Schizophrenia.
Front Psychol. 2022 Apr 1;13:807935. doi: 10.3389/fpsyg.2022.807935. eCollection 2022.
4
An Instrumental Measure of Hand and Facial Movement Abnormalities in Patients With Schizophrenia.
Front Psychiatry. 2022 Mar 4;13:803661. doi: 10.3389/fpsyt.2022.803661. eCollection 2022.
5
The psychosis human connectome project: An overview.
Neuroimage. 2021 Nov 1;241:118439. doi: 10.1016/j.neuroimage.2021.118439. Epub 2021 Jul 30.
8
Exploring the Relationship of Transdiagnostic Mood and Psychosis Symptom Domains with Motor Dysfunction.
Neuropsychobiology. 2020;79(4-5):301-312. doi: 10.1159/000503928. Epub 2019 Dec 18.
9
Motor speech patterns in Huntington disease.
Neurology. 2019 Nov 26;93(22):e2042-e2052. doi: 10.1212/WNL.0000000000008541. Epub 2019 Oct 29.

本文引用的文献

1
Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone.
Hum Mov Sci. 2009 Oct;28(5):633-42. doi: 10.1016/j.humov.2009.07.007. Epub 2009 Aug 18.
2
Extrapyramidal side-effects of antipsychotics in a randomised trial.
Br J Psychiatry. 2008 Oct;193(4):279-88. doi: 10.1192/bjp.bp.108.050088.
3
Aripiprazole: what is the role of dopamine D(2) receptor partial agonism?
Am J Psychiatry. 2007 Sep;164(9):1310-2. doi: 10.1176/appi.ajp.2007.07071043.
4
EPS profiles: the atypical antipsychotics are not all the same.
J Psychiatr Pract. 2007 Jan;13(1):13-24. doi: 10.1097/00131746-200701000-00003.
5
Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study.
Clin Pharmacol Ther. 2007 Apr;81(4):586-94. doi: 10.1038/sj.clpt.6100069. Epub 2007 Jan 18.
7
Quantitative measurement of handwriting in the assessment of drug-induced parkinsonism.
Hum Mov Sci. 2006 Oct;25(4-5):510-22. doi: 10.1016/j.humov.2006.02.004. Epub 2006 May 2.
9
Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology.
CNS Drug Rev. 2004 Winter;10(4):317-36. doi: 10.1111/j.1527-3458.2004.tb00030.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验